Abstract: Described in this disclosure are CRISPRi systems and methods, along with the related compositions and kits, that combine modularity, stable genomic integration, and ease of transfer to diverse bacteria by conjugation. CRISPRi compositions, methods, systems and kits described herein allow for genetic dissection of bacteria, facilitating analyses of microbiome function, antibiotic resistances and sensitivities, as well as comprehensive screening for host-microbe interactions. Embodiments of the invention comprise compositions, methods, systems, and kits for CRISPRi-based repression of gene expression in bacteria.

Abstract: The present disclosure provides methods of treating subjects having a liver disease, and methods of identifying subjects having an increased risk of developing liver disease.

Abstract: The present invention relates, in general to agents that modulate the pharmacological activity of siRNAs. In addition, the invention relates generally to methods and systems for use in assessing the efficacy and safety of a pharmaceutical composition for use in the treatment or prophylaxis of a disease.

Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of FXII RNA in a cell or subject, and in certain instances reducing the amount of FXII protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to prevent, treat, or ameliorate at least one symptom of a thromboembolic condition. Such thromboembolic conditions include deep vein thrombosis, venous or arterial thrombosis, pulmonary embolism, myocardial infarction, and stroke. Such symptoms include pain, shortness of breath, heart burn, cold sweat, fatigue, lightheadedness, dizziness, swelling, cramping, and death. Such compounds, methods, and pharmaceutical compositions are useful to prevent, treat, or ameliorate at least one symptom of hereditary angioedema.

Abstract: Provided is a method for producing washing enzyme having protease resistance. According to the method, the washing enzyme having resistance to protease is obtained by carrying out fusion expression on a gene of the washing enzyme with the gene of a protease inhibitory peptide, thereby facilitating maintaining the stability of various enzyme components in an enzyme-containing detergent, and improving the use effect of the detergent.

Abstract: As disclosed herein, optimal native genomic loci from maize plants have been identified that represent best sites for targeted insertion of exogenous sequences.

Abstract: The present invention relates to the development of high viridiflorol containing variety for enhancing the aroma as well as medicinal properties of Mentha piperita by overexpressing MPTPS4 gene through genetic transformation. This transgenic plant possesses better growth and able to produce essential oil with good quality contains high viridiflorol maximum of about 25% and proportionate decrease in menthone, menthofuran and menthol of Mentha piperita as compared to other control genotype. Mentha piperita (CIM-madhuras) that produces viridiflorol, a molecule of potential demand in perfumery, cosmetics, toiletries, drugs and sanitation products.

Abstract: The gene encoding N-methylputrescine oxidase (MPO) and constructs comprising such DNA are provided, including methods of regulating MPO expression independently or with other alkaloid biosynthesis genes to modulate alkaloid production in plants and host cells. MPO genes or fragments thereof are useful for reducing pyrrolidine or tropane alkaloid production in plants, for increasing pyrrolidine or tropane alkaloid production in plants, and for producing an MPO enzyme in host cells.

Abstract: Certain embodiments of the present invention relate to methods and products for enhancing the rate of photosynthesis in a plant. In addition, certain embodiments relate to transgenic plants and progeny thereof which comprise an exogenous Rieske Iron Sulphur protein.

Abstract: The present invention refers to a plant or plant part comprising a polynucleotide encoding a wildtype or mutated cellulose synthase (CESA) polypeptide, the expression of said polynucleotide confers to the plant or plant part tolerance to CESA-inhibiting herbicides, such as azines.

Abstract: The present invention provides for soybean plant and seed comprising transformation event MON89788 and DNA molecules unique to these events. The invention also provides methods for detecting the presence of these DNA molecules in a sample.

Abstract: The present invention relates to a tomato, Solanum lycopersicum, plant that is resistant to Tobamovirus, wherein the plant comprises one or more genomic sequences conferring Tobamovirus resistance. More specifically the invention relates to a tomato plant that is resistant to Tomato Brown Rugose Fruit Virus (TBRFV). The present invention further relates to a genomic sequence or locus providing resistance to Tobamovirus. In addition, the present invention relates to methods for proving a tomato plant that is resistant to Tobamovirus.

Abstract: The invention relates to genes which may be utilized to induce resistance to soybean cyst nematode (SCN) and/or other abiotic or biotic stresses. More specifically the present disclosure provides genes that, when inactivated and/or overexpressed (for example, overexpression of genes encoding kinase-dead mutants) in a plant, particularly, a soybean plant, can confer upon the plant resistance to SCN and/or other abiotic or biotic stresses. Methods of using these genes to obtain plants, particularly soybean plants, that are resistant to SCN and/or other abiotic or biotic stresses are also provided.

Abstract: Methods are described for selecting or producing a cereal plant comprising a functional restorer gene for wheat G-type cytoplasmic male sterility and nucleic acids for use therein.

Abstract: A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.

Abstract: The present invention provides a composition comprising i) a pseudotyped retroviral vector particle comprising a) one envelope protein with antigen-binding activity, wherein said envelope protein is a recombinant protein that does not interact with at least one of its original receptors and is fused at its ectodomain to a polypeptide comprising an antigen binding domain specific for CD62L, and wherein said envelope protein is protein G, HN or H derived from the Paramyxoviridae family, b) one envelope protein with fusion activity derived from the Paramyxoviridae family, and T cells expressing CD62L. Alternatively, when said polypeptide comprising an antigen binding domain is specific for a tag of a tagged polypeptide instead of the antigen binding domain specific for CD62L, wherein said tagged polypeptide binds specifically to CD62L, then the composition comprises further said tagged polypeptide.

Abstract: The present disclosure relates to one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for increasing production of a belatacept-similar protein and micro-RNA associated with decreasing production of tumor necrosis factor alpha. Embodiments of the present disclosure can be used as a therapy or a treatment for a subject that has a condition whereby the subject's immune system is, or is likely to become, dysregulated and where the production of the belatacept-similar protein and decreased production of tumor necrosis factor alpha may be of therapeutic benefit.

Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues of organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provide dare methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.

Abstract: In the present invention, lymphocytes are efficiently grown by culturing lymphocytes in the presence of a novel recombinant fibronectin fragment.

Abstract: A filter for filtering nucleated cells that includes a body containing at least either a metal or a metal oxide as its main component; and plural through holes, each of which have a shape other than a square shape, formed therein. An arithmetic average roughness of a first side of the filter part is smaller than a size of a nucleus of the nucleated cells to be filtered.

Abstract: Provided are chemical inducers of lineage reprogramming (CiLR) which include glycogen synthase kinase inhibitors, TGF? receptor inhibitors, cyclic AMP agonists or histone acetylators. Also provided is a method of inducing lineage reprograming in a partially or completely differentiated cell of a first type into a cell with characteristics of a second and different lineage. The method includes: contacting a cell with the CiLR for a sufficient period of time to result in reprograming the cell into a modified XEN-like cell which is subsequently programmed into a cell with characteristics of a second and different lineage.

Abstract: This present disclosure relates to a bioengineering approach based on microphysiological culture to mimic tissue-tissue interface. Accordingly, the present disclosure provides methods, compositions and kits related to the approach.

Abstract: The disclosure provides a method of freezing an aggregate of pluripotent stem cell-derived cardiomyocytes, comprising: (i) immersing an aggregate of pluripotent stem cell-derived cardiomyocytes in a cryoprotective solution; and (ii) freezing the aggregate immersed in the cryoprotective solution. The disclosure also provides a frozen aggregate of pluripotent stem cell-derived cardiomyocytes frozen by the method.

Abstract: The present invention provides a cardiomyocyte maturation promoter. The present invention provides a cardiomyocyte maturation promoter comprising one or more compounds selected from 2-methoxy-5-((Z)-2-(3,4,5-trimethoxyphenyl)vinyl)phenol, (1-ethyl-1H-benzotriazol-5-yl)methyl (2-(2-methoxy-4-methylphenyl)-4-methyl-1,3-thiazol-5-yl)carbamate, (2?beta)-22-oxovincaleukoblastine, 2-(2-(4-chlorophenyl)ethyl)-6-(2-furyl)-3H-imidazo[4,5-b]pyridine, 4,5-anhydro-1,2-dideoxy-4-methyl-2-((N-(morpholin-4-ylacetyl)-L-alanyl-O-methyl-L-tyrosyl)amino)-1-phenyl-L-threo-pent-3-ulose, 3-(3-methoxyphenyl)-N7,N7-dimethylisoquinoline-1,7-diamine, methyl 4-(2-benzylbenzoyl)-2,5-dimethyl-1H-pyrrole-3-carboxylate, 2?-(4-aminophenyl)-1H,1?H-2,5?-bibenzimidazol-5-amine, and salts thereof.

Abstract: An object of the present invention is to provide a method for producing insulin-producing cells having sufficient glucose responsiveness from mesenchymal stem cells, an insulin-producing cell having sufficient glucose responsiveness, a cell structure containing the insulin-producing cell, and a pharmaceutical composition.

Abstract: The present invention chiefly aims to provide a process for directly inducing insulin-producing cells from somatic cells without performing artificial gene transfer. The present invention can include a process for producing an insulin-producing cell by inducing differentiation directly from a somatic cell, the process comprising a step of culturing the somatic cell in the presence of a cAMP inducer, and six members selected from the group consisting of a GSK3 inhibitor, a TGF-? inhibitor, a BMP inhibitor, a p53 inhibitor, a PI3K inhibitor, a Notch inhibitor and a RAR agonist, or all members thereof. The insulin-producing cells obtained by the present invention are useful in regenerative medicine and the like.

Abstract: An in vitro microfluidic intestine on-chip is described herein that mimics the structure and at least one function of specific areas of the gastrointestinal system in vivo. In particular, a multicellular, layered, microfluidic intestinal cell culture, which is some embodiments is derived from patient's enteroids-derived cells, is described comprising L cells, allowing for interactions between L cells and gastrointestinal epithelial cells, endothelial cells and immune cells. This in vitro microfluidic system can be used for modeling inflammatory gastrointestinal autoimmune tissue, e.g., diabetes, obesity, intestinal insufficiency and other inflammatory gastrointestinal disorders. These multicellular-layered microfluidic intestine on-chips further allow for comparisons between types of gastrointestinal tissues, e.g., small intestinal duodenum, small intestinal jejunum, small intestinal ileum, large intestinal colon, etc., and between disease states of gastrointestinal tissue, i.e.

Abstract: The present invention relates to the identification of a genomic integration site for heterologous polynucleotides in Chinese Hamster Ovary (CHO) cells resulting in high RNA and/or protein production. More specifically it relates to CHO cells comprising at least one heterologous polynucleotide stably integrated into the S100A gene cluster of the CHO genome and to methods for the production of said CHO cells. Further, the invention relates to a method for the production of a protein of interest using said CHO cell and to the use of said CHO cell for producing a protein of interest at high yield. Integration within these specific target regions leads to reliable, stable and high yielding production of an RNA and/or protein of interest, encoded by the heterologous polynucleotide.

Abstract: Provided herein are compositions, systems, kits, and methods for generating human podocyte cells by contacting human nephron progenitor cells with an FGFR pathway inhibitor, a BMP pathway inhibitor, and a WNT pathway inhibitor. In certain embodiments, the nephron progenitor cells are further contacted with at least one factor selected from: BMP4, BMP7, lysophosphatidic acid, and gamma-secretase inhibitor XX. In certain embodiments, the contacting the nephron progenitor cells is performed under serum-free conditions.

Abstract: The present disclosure relates generally to an improved gene expression system in the field of recombinant gene expression. The invention relates to a system showing an improved yield and quality of protein production and methods for increasing production of a protein produced by cultured cells, particularly cultured eukaryotic cells.

Abstract: This application relates to recombinant adeno-associated virus (rAAV) packaging and/or producer cell lines which have been engineered to reduce expression and/or activity of one or more genes and/or proteins to increase rAAV titers. The methods of generating the engineered cell lines have also been described herein.

Abstract: Provided are vaccines, polypeptides and polynucleotides based on mutant CALR and JAK2 sequences, vectors, host cells, viruses, and methods of making and using them. The disclosure also provides methods of inducing an immune response and methods of treating, preventing, reducing a risk of onset or delaying the onset of a clinical condition characterized by an expression of JAK2V617F or CALR exon 9 mutant, or both JAK2V617F and CALR exon 9 mutant, wherein the method comprises a plurality of administrations of any of the compositions comprising polynucleotides, polypeptides or vectors disclosed herein.

Abstract: Methods for continuously inactivating a virus during manufacture of a protein are provided. Steps include (1) combining, at a single predetermined volumetric ratio, a composition including the protein, and a composition including a virus-inactivation reagent, to obtain a treatment composition having a predetermined property for inactivation of a virus; (2) transferring the treatment composition to a treatment vessel; (3) incubating the treatment composition in the treatment vessel at predetermined conditions; and (4) subjecting the treatment composition to a post-treatment processing operation. The single predetermined volumetric ratio has been selected to ensure that the predetermined property of the treatment composition is maintained across a range of concentrations predicted for the protein in the composition including the protein.

Abstract: The present invention provides compositions of CD 180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.

Abstract: Provided for herein are mutant VSV-G polypeptides, compositions comprising the same, and methods of using the same. Also provided for herein are polypeptides and compositions that bind to CD7 and uses thereof. Also provided for herein are polypeptides and compositions that bind to CD8 and uses thereof.

Abstract: Provided is a method for large-scale preparation of a purified preparation of a recombinant lentiviral vector at the GMP grade. The method comprises: (a) providing raw material feed liquid to be purified that comprises recombinant viral vectors; (b) carrying out a microfiltration treatment on the feed liquid to obtain a microfiltered filtrate comprising the recombinant viral vectors; (c) optionally concentrating the filtrate to obtain a concentrated filtrate; (d) purifying the filtrate obtained in the previous step by means of chromatography to obtain a crude pure product comprising the recombinant viral vectors; and (e) subjecting the crude pure product obtained in the previous step to liquid exchange and elaborate purification to obtain the purified recombinant viral vectors.

Abstract: Provided are: a DNA polymerase mutant having reverse transcriptase activity, the DNA polymerase mutant including a sequence consisting of twelve specific amino acids A1-A12, wherein the DNA polymerase mutant having reverse transcriptase activity is characterized in that the A3 and/or A10 amino acid is substituted by a basic amino acid residue different from that prior to the introduction of mutation; a kit and a composition including the DNA polymerase; a method for producing the DNA polymerase; and a method for modifying an existing DNA polymerase having reverse transcriptase activity.

Abstract: The present invention provides engineered DNA polymerase polypeptides and compositions thereof, as well as polynucleotides encoding the engineered DNA polymerase polypeptides. The invention also provides methods for use of the compositions comprising the engineered DNA polymerase polypeptides for diagnostic and other purposes.

Abstract: Provided are compositions comprising recombinant DNA polymerases that include amino acid substitutions, insertions, deletions, and/or exogenous features that confer modified properties upon the polymerase for enhanced single molecule sequencing. Such properties include increased resistance to photodamage, and can also include enhanced metal ion coordination, reduced exonuclease activity, reduced reaction rates at one or more steps of the polymerase kinetic cycle, decreased branching fraction, altered cofactor selectivity, increased yield, increased thermostability, increased accuracy, increased speed, increased readlength, and the like. Also provided are nucleic acids which encode the polymerases with the aforementioned phenotypes, as well as methods of using such polymerases to make a DNA or to sequence a DNA template.

Abstract: Provided herein is technology relating to molecular biological manipulation of genes and genomes and particularly, but not exclusively, to CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) methods, compositions, systems, and kits for improved genetic editing.

Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

Abstract: Methods and kits for quantifying adenosine-containing molecules within an aqueous composition. Particularly, the methods utilize a competitive fluorescence-polarization and FRET-based assays that directly measure the production of adenosine-containing compounds, particularly S-adenosylhomocysteine (AdoHcy) compounds produced by MTases. The generation of AdoHcy can be quantified by displacing a novel fluorescent probe comprising a 5-carboxytetramethylrhodamine fluorophore covalently bound to an adenosine scaffold from a catalytically inert 5?-methylthioadenosine nucleosidase (MTAN) variant. One or more of the reaction materials can be pre-loaded into wells within multi-well reaction plates as a kit, which can be used to determine the enzymatic activity of MTases or conduct drug screening for potential inhibitors in a high-throughput format.

Abstract: The invention concerns a genetically modified microorganism expressing a functional type I or II RuBisCO enzyme and a functional phosphoribulokinase (PRK), and in which the glycolysis pathway is at least partially inhibited, said microorganism being genetically modified so as to produce an exogenous molecule and/or to overproduce an endogenous molecule. According to the invention, the oxidative branch of the pentose phosphate pathway may also be at least partially inhibited. The invention also concerns the use of such a genetically modified microorganism for the production or overproduction of a molecule of interest and processes for the synthesis or bioconversion of molecules of interest.

Abstract: The present disclosure relates to recombinant polypeptides that have olivetolic acid cyclase activity, nucleic acids encoding these recombinant polypeptides, recombinant host cells that produce these recombinant polypeptides, and compositions comprising the recombinant polypeptides, nucleic acids, and/or recombinant host cells. The present disclosure also relates to uses of these recombinant polypeptides, nucleic acids encoding them, and recombinant host cells comprising them, in methods for the preparation of cannabinoids and cannabinoid precursors.

Abstract: Glycerol-free enzyme formulations are described. In some embodiments, a glycerol-free enzyme formulation is stabilized by high salt concentration. The glycerol free enzyme formulation may comprise a reverse transcriptase enzyme.

Abstract: Described herein is a method for preparing an amino salt compound, the method including: i) providing a carbonyl compound; ii) reacting the carbonyl compound provided according to (i) in the presence of a transaminase with ii-a) at least one primary amine; and ii-b) at least one carboxylic acid; thereby obtaining a mixture including an at least partially crystallized amino salt compound including a cation and a carboxylate anion based on the at least one carboxylic acid added according to (ii-b). Also described herein is an amino salt compound obtained or obtainable by the method and to the amino salt compound, and a composition including a) an amine of general formula (IIa); and b) at least one carboxylic acid of general formula (III).

Abstract: Host cells that are engineered to produce benzylisoquinoline alkaloid (BIAS) precursors, such as norcoclaurine (NC) and norlaudanosoline (NL), are provided. The host cells may have one or more engineered modifications selected from: a feedback inhibition alleviating mutation in a enzyme gene; a transcriptional modulation modification of a biosynthetic enzyme gene; an inactivating mutation in an enzyme; and a heterologous coding sequence. Also provided are methods of producing a BIA of interest or a precursor thereof using the host cells and compositions, e.g., kits, systems etc., that find use in methods of the invention.

Abstract: A fermentation process is provided for the synthesis of Nigericin from Streptomyces sp. having accession number MCC 0151 and its isolation with high yield. A microbial inoculant composition is provided, comprising a biologically pure culture of Streptomyces sp. MCC 0151 for the exclusive production of Nigericin with high yield.

Abstract: The disclosure discloses a method for chemically synthesizing a Helicobacter pylori core lipopolysaccharide oligosaccharide antigen carbohydrate chain, and belongs to the technical field of carbohydrate chemistry. The disclosure uses D-glucose, D-galactose and D-mannose as starting materials, which undergo a series of protection and deprotection reactions to prepare eight monosaccharide blocks. The eight monosaccharide block compounds as shown in formulas 2 to 9 undergo glycosylation reactions under catalysis of corresponding activating reagents, to prepare H. pylori lipopolysaccharide core oligosaccharide antigen fragments as shown in formula 1. The disclosure further combines the synthesized oligosaccharide fragments with a chip to make a carbohydrate chip, screens the optimal antigen fragments using patient serum, or combines the synthesized oligosaccharide fragments with carrier proteins to make glycoconjugates.

Abstract: The present invention relates to an in vitro or in vivo process for producing a glucuronide comprising a glucuronic acid moiety bound to a phenolic hydroxyl group or a phenolic carboxyl group. Also provided are expression vectors, nucleic acids, polypeptides, and recombinant microbial cells useful in carrying out the process and prodrugs produced by the process.